Repository of the Academy's Library

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial

Lechat, P. and Brunhuber, K. W. and Hofmann, R. and Kuhn, P. and Nesser, H. J. and Slany, J. and Weihs, W. and Wiedermann, C. and Wimmer, H. and Mieghem, W. van and Préda, István and Csanády, Miklós and Cserhalmi, L. and Edes, I. and Gesztesi, T. and Karpati, P. and Simon, K. and Tarjan, J. (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet, 353 (9146). pp. 9-13. ISSN 0140-6736 (print), 1474-547X (online)

[img] PDF
1017192.pdf
Restricted to Registered users only

Download (80Kb) | Request a copy

Abstract

Background In patients with heart failure, beta-blochade has improved morbidity and left-ventricular function, but the impact on survival is uncertain. We investigated the efficacy of bisoprolol, a beta(1) selective adrenoceptor blocker in decreasing all-cause mortality in chronic heart failure. Methods In a multicentre double-blind randomised placebo-controlled trial in Europe, we enrolled 2647 symptomatic patients in New York Heart Association class III or IV, with left-ventricular ejection fraction of 35% or less receiving standard therapy with diuretics and inhibitors of angiotensin-converting enzyme. We randomly assigned patients bisoprolol 1.25 mg (n=1327) or placebo (n=1320) daily, the drug being progressively increased to a maximum of 10 mg per day. Patients were followed up for a mean of 1.3 years. Analysis was by intention to treat. Findings CIBIS-II was stopped early, after the second interim analysis, because bisoprolol showed a significant mortality benefit. All-cause mortality was significantly lower with bisoprolol than on placebo (156 [11.8%] vs 228 [17.3%] deaths with a hazard ratio of 0.66 (95% CI 0.54-0.81, p<0.0001). There were significantly fewer sudden deaths among patients on bisoprolol than in those on placebo (48 [3.6%] vs 83 [6.3%] deaths), with a hazard ratio of 0.56 (0.39-0.80, p=0.0011). Treatment effects were independent of the severity or cause of heart failure. Interpretation beta-blocker therapy had benefits for survival in stable heart-failure patients. Results should not, however, be extrapolated to patients with severe class IV symptoms and recent instability because safety and efficacy has not been established in these patients.

Item Type: Article
Additional Information: Több mint 100 szerző a szerzőségben
Subjects: R Medicine / orvostudomány > RZ Other systems of medicine / orvostudomány egyéb területei
Depositing User: Erika Bilicsi
Date Deposited: 13 Nov 2012 13:41
Last Modified: 13 Nov 2012 14:45
URI: http://real.mtak.hu/id/eprint/3358

Actions (login required)

View Item View Item